Eledon Pharmaceuticals, Inc.
NASDAQ: ELDN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David-Alexandre C. Gros
- Employees
- 31
- Headquarters
- Irvine, United States
- IPO year
- 2014
- Market cap
- $237.4M
- Website
- https://eledon.com
Loading ELDN…
Loading profile data…Frequently asked questions about ELDN
What does Eledon Pharmaceuticals, Inc. (ELDN) do?
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to...
Where does ELDN trade?
Eledon Pharmaceuticals, Inc. (ELDN) trades on the NASDAQ Capital Market.
What sector is ELDN in?
Eledon Pharmaceuticals, Inc. (ELDN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Eledon Pharmaceuticals, Inc.?
David-Alexandre C. Gros is the chief executive officer of Eledon Pharmaceuticals, Inc. (ELDN).
Where is Eledon Pharmaceuticals, Inc. headquartered?
Eledon Pharmaceuticals, Inc. is headquartered in United States.
Does ELDN pay a dividend?
Eledon Pharmaceuticals, Inc. (ELDN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ELDN go public?
Eledon Pharmaceuticals, Inc. (ELDN) completed its initial public offering in 2014.